The Pharma & Biotech stock index grew by more than 32.5% in 2014, and the increasing number of public CROs saw their stock prices rise as well. In 2014, the clinical development industry saw an increased shift toward Risk-Based Monitoring methodologies and an increased reliance on eClinical technologies.
View File